Abstract 140P
Background
Colorectal adenomas (AA) are pre-cursors for 85% of the cancers. Methylation and copy-number alterations are well described in colorectal cancer (CRC) context. We aimed to investigate these signals on AA sub-types.
Methods
Whole-genome Enzymatic Sequencing was performed on advanced adenoma (AA) and adjacent control (CNT) tissues of serrated (14), tubular (26), tubulovillous (24) and villous (10) patient samples, alongside colorectal cancer (CRC) stage I samples (23). Differential methylation analysis pipeline was applied, first to identify regions that are significantly altered between all AA subgroups and CNT tissue and then further investigated for sub-type and CRC I level differences. Additionally, mutation and copy-number alteration (CNA) detection were performed, alongside pathway enrichment.
Results
Initial differential methylation analysis revealed 7725 regions significantly altered between AA and CNT tissue. 137 and 2093 and 91 of those were hypermethylated between serrated vs tubular, serrated vs tubulovillous, tubular vs tubulovillous sub-types respectively. Main pathways, differentiating serrated adenomas from the rest, belong to cAMP signalling, regulation of pluripotency of stem cells, while regions separating tubular and tubulovillous were enriched for WNT signalling. These differential signals could not be seen in stage I CRC samples, which presented CNT-like methylation. The CNA signals were mostly present in tubular or tubulovillous samples. The most frequent signals could be seen in chr7, 12, 19 and 20. Majority of CRC I exhibited CNA in chr 7, 8 and 20, indicating difference processes to be in place between AA and CRC I progression. Differences could also be observed on sub-type level, when looking at tumour mutational burden and specific mutations in APC and KRAS genes.
Conclusions
Colorectal adenoma histological subtypes show distinctly different methylation, CNA and mutational signals, between groups and compared CRC I. These findings are especially important when developing early detection or cancer prevention tests trying to capture adenoma (sub-type level) signatures. These results have been followed by plasma-based biomarker detection studies for pre-cancer screening intent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Universal Diagnostics S.A.
Funding
Universal Diagnostics S.A.
Disclosure
F.M. Mancuso, P. Canal Noguer, K. Kruusmaa: Financial Interests, Personal, Full or part-time Employment: Universal Diagnostics.
Resources from the same session
186P - Pooled efficacy and safety data of alectinib (A) vs. crizotinib (C) from the randomized phase III ALEX and J-ALEX trials
Presenter: Marco Tagliamento
Session: Poster session 01
187P - Ipatasertib and atezolizumab in cancers with increased PI3K-AKT pathway activity: First results from the CRAFT trial
Presenter: Christoph Heilig
Session: Poster session 01
188P - The landscape of SMARCA2 genomic alterations in Chinese cancer patients
Presenter: Chen Jiaqi
Session: Poster session 01
189P - Design and enrollment for a classifier development study for a blood-based multi-cancer early detection (MCED) test
Presenter: Christopher Douville
Session: Poster session 01
190P - Quantitative serum tumor markers (CEA, CA19-9, and CA-125) are independently predictive of survival in patients with appendiceal adenocarcinoma
Presenter: John Paul Shen
Session: Poster session 01
191P - Novel approach to proficiency testing demonstrates wide gaps in biomarker quality for colon cancer treatment
Presenter: Kassandra Bisson, Brandon Sheffield
Session: Poster session 01
192P - Impact of oncogenic fibroblast growth factor receptor (FGFR) alterations in patients with advanced solid tumors in a real-world setting
Presenter: Hussein Sweiti
Session: Poster session 01
194P - Early kinetics of C-reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: A multi-center cohort study
Presenter: Dominik Barth
Session: Poster session 01
195P - Identification of biomarkers associated with checkpoint inhibitor pneumonitis based on serum proteomic approach and construction of an online interactive visual prediction model
Presenter: Xiaohui Jia
Session: Poster session 01
196P - Serum metabolomics to determine survival of immunotherapy for advanced non-small cell lung cancer: Metabolomic analysis based on two cohorts
Presenter: Yanjun Xu
Session: Poster session 01